Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 03/23/23
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific ConferenceGlobeNewsWire • 03/20/23
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsGlobeNewsWire • 03/02/23
All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong BuyZacks Investment Research • 01/10/23
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect?Zacks Investment Research • 12/16/22
Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 12/09/22
Wall Street Analysts Predict a 141% Upside in Dyne Therapeutics, Inc. (DYN): Here's What You Should KnowZacks Investment Research • 11/30/22
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 11/03/22
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 10/31/22
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 CongressGlobeNewsWire • 10/11/22
Dyne Therapeutics to Present at Chardan's 6th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/27/22
Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual EventGlobeNewsWire • 09/12/22
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/22
Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1GlobeNewsWire • 09/06/22
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 09/06/22
Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of DevelopmentGlobeNewsWire • 08/29/22
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids ResearchGlobeNewsWire • 08/10/22
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 08/04/22
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1GlobeNewsWire • 07/12/22